GLTO

#11856
Damora Therapeutics, Inc. Common Stock
28.69 USD
-0.76%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
28.69
28.69
1年のレンジ
2.01
38.33
1日の変化
-0.76%
月次変化
-6.00%
6か月変化
+917.38%
1年の変化
+613.68%
以前の終値
28.91
始値
28.69
Bid
Ask
安値
28.69
High
28.69
ボリューム
10
チャート全体を表示

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 1.59 B
  • Employee 7
  • Founded 2011
  • CEO Hans T. Schambye
  • Website www.damoratx.com
  • Headquarter Delaware, United States
  • FIGI BBG00XMLGWC5
  • Industry Technology
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-5.78
売上高対価格比率
28.96

Galecto Inc

Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark. The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need.

ニュース